Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. (BRTX) covers events occurring between July 8, 2026, and July 16, 2026. The report details significant corporate governance changes, including amendments to executive employment agreements, the resignation of key officers and directors, and the appointment of new leadership.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a potential contingent liability:
- Potential Severance Liability: Approximately $2.85 million in aggregate cash severance payments, plus accelerated equity vesting and benefits, if the resignations of Lance Alstodt and Robert Kristal are deemed to be for "Good Reason" under their employment agreements.
Material Changes
The filing reports the following material changes to the company's leadership and contractual obligations:
- Employment Agreement Amendments: On July 8, 2026, the company amended agreements for Lance Alstodt (CEO), Robert Kristal (CFO), and Francisco Silva (VP, R&D). The amendments narrowed the definition of "Change in Control" triggering severance and accelerated vesting, removing triggers related to a change in the majority of the Board.
- Executive Resignations: On July 13, 2026, Lance Alstodt (CEO, President, Chairman) and Robert Kristal (CFO) resigned, asserting "Good Reason" based on a "Change in Control" (change in Board majority) that occurred in June 2026. They are seeking the $2.85 million severance package.
- Director Resignation: David Rosa resigned as a director and from all board committees effective July 11, 2026.
- Leadership Appointment: Katharyn Field was appointed CEO, President, and Interim CFO effective July 13, 2026. She is no longer considered an independent director.
- Board Elections: Esha Randhawa and Steven Brown were elected as directors to fill vacancies. The board committees were reconstituted accordingly.
Outlook, Risks, and Contingencies
Management Commentary and Dispute: The Board has not accepted the resignations of Messrs. Alstodt and Kristal as being for "Good Reason" nor conceded that a "Change in Control" occurred under the terms of their agreements. The Company has reserved all rights and defenses regarding these claims.
Investigation: The Board has authorized an investigation by special counsel into the negotiation, approval, execution, and amendment of the executive employment agreements. Pending the investigation's completion, no severance payments or benefits will be made other than accrued base salary and amounts required by wage-payment laws.
Risks: The primary risk is the potential financial outflow of approximately $2.85 million plus equity acceleration if the executives' claims are upheld. Additionally, the company faces interim leadership instability while searching for a permanent CFO.
Investor Verification Checklist
- Verify the status of the special counsel investigation into the employment agreements.
- Monitor for any legal filings or settlements regarding the $2.85 million severance claim by Alstodt and Kristal.
- Confirm the timeline and outcome of the search for a permanent Chief Financial Officer.
- Review the upcoming disclosure of compensation arrangements for the new CEO, Katharyn Field.
- Assess the impact of the June 2026 Board composition changes (related to the Loan Agreement) on future governance stability.